Shalby Ltd

- There is no explicit mention of current or future fundraising through debt or equity in the provided transcript excerpt. - The company highlights a strong balance sheet with low gearing (0.2 net debt of around INR279 crores). - Focus appears to be on internal cash flow and strategic investments, including acquisitions and expansions (e.g., INR300 crores acquisition, INR250 crores investment in Mumbai hospital). - Dividend distribution is being reserved to maintain cash for ongoing investments. - Management emphasizes growth through operational expansion and partnerships rather than raising external funds at this stage.

- Shalby is expanding capacity in ROCE-accretive businesses. - Recent large acquisition of nearly INR 300 crores in last 15 months. - Adding a hospital in Mumbai with an investment of over INR 250 crores. - Sanar hospital optional bed expansion from 130 to 180 beds planned; timelines depend on occupancy and approvals. - Franchisee business growing selectively with focus on quality partnerships; minimal capital employed but requires management bandwidth. - Implant business investing significantly for growth; product development and regulatory approvals ongoing. - Technology investments planned to accelerate growth, especially in home care business in future phases. - Mumbai hospital project to commence post regulatory approvals and finalization of agreements; construction expected within 6-9 months once started.

- Hospital business expected to grow at double-digit rates, maintaining 5-7 years’ growth trend. - Sanar Hospital (newer business) anticipated to grow at higher double-digit rates until capacity is exhausted. - Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. - Two new implant products planned to launch in FY '26, expected to add INR40-50 crores yearly revenue after regulatory approvals. - Long-term implant product pipeline includes 5-6 products, given a roughly 3-year gestation period per product. - Overall consolidated revenue for FY '26 expected to see high single-digit growth or better compared to FY '25. - Capacity in hospital setups has room to double revenue without expansion; expansion projects (e.g., Mumbai hospital) underway but delayed. - Focus on talent acquisition and super specialty verticals to drive future growth.

- Hospital business expected to grow at double-digit rates for next 5-7 years due to unutilized capacity and ongoing expansions (Shanay Shah, Page 11). - Sanar Hospital poised for higher double-digit growth; revenue and patient counts increasing steadily, EBITDA expected to turn positive within the year (Page 10-11). - Implant business is in high growth, having grown 4x in Indonesia, 35-40% in the US, and 2.5x in India; expected to maintain high double-digit growth trajectory driven by new product launches contributing INR40-50 crores annually (Page 11-13). - Overall consolidated revenue for FY '26 expected to be better than FY '25, suggesting higher single-digit to double-digit growth (Amit Pathak, Page 15-16). - Operating performance may improve as investments in talent and infrastructure mature; EBITDA impact due to investing phase expected to reverse (Page 9-10). - Tax rate for FY '26 projected around 25% (Page 12).

The transcript on page 15 of Shalby Limited's Q4 FY '25 earnings call does not provide a specific figure or detailed commentary on the current or expected order book or pending orders. Key points related to business growth and outlook include: - Hospital business expected to continue double-digit growth. - Implant business anticipated to grow at higher double-digit rates due to a lower base. - Implant segment grew approximately 50% on a 12-month consolidated basis in FY '25. - Launch of two new implant products planned, potentially contributing INR40-50 crores annually. - Expansion plans include launching operations in 4-5 new countries in '25-'26. - Ongoing focus on supply chain and cost efficiencies to improve margins and operational performance. No explicit update on order book or pending order backlog is mentioned in the provided transcript excerpt.